Hialeah

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Asthma5 trials
• Fatty liver disease (MASLD/MASH)5 trials
• COPD4 trials
• Liver cirrhosis2 trials
• Irritable bowel syndrome1 trial
• Lung cancer1 trial

Phase

• Phase 312 trials
• Phase 23 trials
• Phase 11 trial

Status

• Recruiting8 trials
• Completed6 trials
• Active, not recruiting2 trials

Lead sponsor

• GlaxoSmithKline16 trials

Running trials

• Recruiting

  A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07704892· Phase 3· GlaxoSmithKline· Source

  Contact: Isaac Bassan (principal investigator)

• Recruiting

  A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· Phase 3· GlaxoSmithKline· Source

  Contact: Isaac Bassan (principal investigator)

• Recruiting

  A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· Phase 2· GlaxoSmithKline· Source

  Contact: Isaac Bassan (principal investigator)

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

  Contact: Isaac Bassan (principal investigator)

• Recruiting

  A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

  NCT07221227· Phase 3· GlaxoSmithKline· Source

  Contact: Isaac Bassan (principal investigator)

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· GlaxoSmithKline· Source

  Contact: Alberto Manzor (principal investigator)

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Luis Rangel (principal investigator)

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

  Contact: Alberto Manzor (principal investigator)

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

  NCT06154837· Phase 1· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)4 recruiting
• COPD2 recruiting
• Liver cirrhosis2 recruiting
• Irritable bowel syndrome1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

  NCT05281523· Phase 3· GlaxoSmithKline· Source

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source